[go: up one dir, main page]

SE8304818D0 - A MEDICINE HAVING ANTI-ULCER, SPASMOLYTIC AND LOCALLY ANESTHETIC EFFECT - Google Patents

A MEDICINE HAVING ANTI-ULCER, SPASMOLYTIC AND LOCALLY ANESTHETIC EFFECT

Info

Publication number
SE8304818D0
SE8304818D0 SE8304818A SE8304818A SE8304818D0 SE 8304818 D0 SE8304818 D0 SE 8304818D0 SE 8304818 A SE8304818 A SE 8304818A SE 8304818 A SE8304818 A SE 8304818A SE 8304818 D0 SE8304818 D0 SE 8304818D0
Authority
SE
Sweden
Prior art keywords
spasmolytic
ulcer
medicine
active ingredient
anesthetic effect
Prior art date
Application number
SE8304818A
Other languages
Swedish (sv)
Other versions
SE8304818L (en
SE462420B (en
Inventor
L Benes
A Babulova
V Nosalova
S Stolc
A Borovansky
V Bauer
Original Assignee
Slovenska Akademia Vied
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slovenska Akademia Vied filed Critical Slovenska Akademia Vied
Publication of SE8304818D0 publication Critical patent/SE8304818D0/en
Publication of SE8304818L publication Critical patent/SE8304818L/en
Publication of SE462420B publication Critical patent/SE462420B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to pharmaceutical compositions with antiulcer, spasmolytic and local anaesthetic action, which are particularly suitable for oral administration and contain as active ingredient trans-2-(1-pyrrolidinyl)cyclohexyl 3-n-pentyloxycarbanilate or one of its salts with a pharmaceutically suitable inorganic or organic acid and, preferably, the corresponding hydrochloride, together with a physiologically acceptable vehicle and/or an antacid component. The compositions according to the invention prevent at a daily dose of 10 to 200 mg the formation of tumours, inhibit their spread and shorten the duration of healing, the dosage being less than with conventional compositions having the same action. Combination of the active ingredient with antacid substances is particularly advantageous.
SE8304818A 1983-09-13 1983-09-08 APPLICATION OF TRANS-2- (1-PYRROLIDINYL) -CYCLOHEXYL ESTER OF 3-N-PENTYLOXICARBANIC ACID FOR PREPARATION OF A MEDICINAL PRODUCT WITH AN ANGENTIC EFFECT SE462420B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833333008 DE3333008A1 (en) 1983-09-13 1983-09-13 Pharmaceutical compositions with antiulcer, spasmolytic and local anaesthetic action

Publications (3)

Publication Number Publication Date
SE8304818D0 true SE8304818D0 (en) 1983-09-08
SE8304818L SE8304818L (en) 1985-03-09
SE462420B SE462420B (en) 1990-06-25

Family

ID=6208945

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8304818A SE462420B (en) 1983-09-13 1983-09-08 APPLICATION OF TRANS-2- (1-PYRROLIDINYL) -CYCLOHEXYL ESTER OF 3-N-PENTYLOXICARBANIC ACID FOR PREPARATION OF A MEDICINAL PRODUCT WITH AN ANGENTIC EFFECT

Country Status (6)

Country Link
JP (1) JPS6067421A (en)
BE (1) BE897823A (en)
CH (1) CH654743A5 (en)
DE (1) DE3333008A1 (en)
NL (1) NL8303098A (en)
SE (1) SE462420B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103380A (en) 1998-06-03 2000-08-15 Cabot Corporation Particle having an attached halide group and methods of making the same

Also Published As

Publication number Publication date
SE8304818L (en) 1985-03-09
NL8303098A (en) 1985-04-01
DE3333008C2 (en) 1990-06-21
DE3333008A1 (en) 1985-03-21
JPH045003B2 (en) 1992-01-30
BE897823A (en) 1984-01-16
CH654743A5 (en) 1986-03-14
SE462420B (en) 1990-06-25
JPS6067421A (en) 1985-04-17

Similar Documents

Publication Publication Date Title
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
ES2188782T3 (en) PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACINE.
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
ATE204160T1 (en) FORMULATION FOR INHALATION APPLICATION
MX9700081A (en) Tacrine pharmaceutical compositions.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
KR910009273A (en) Pharmaceutical composition for treating gastrointestinal pain
ATE92762T1 (en) MEDICATION.
KR970061244A (en) Pharmaceutical composition for treating dementia
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
AU8424091A (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
KR890004705A (en) Antiviral agents
IL126199A (en) Nasal pharmaceutical compositions for the prophylaxis of delayed emesis
SE8304818D0 (en) A MEDICINE HAVING ANTI-ULCER, SPASMOLYTIC AND LOCALLY ANESTHETIC EFFECT
DE3688787D1 (en) PRODUCTION OF A MEDICINE AGAINST ARTHRITIS AND RHEUMATISM.
KR880003973A (en) Pharmacologically active compounds and uses
KR890001558A (en) Zephyron and its pharmaceutically acceptable acid addition salts alleviate panic disorder
US3499087A (en) Method for treating ulcers with benzoyl esters of 2-tertiary amino-1-phenyl ethanols
JPH0395114A (en) Therapeutic medicine for peptic ulcer at stomach and duodenum
US3198703A (en) Method of producing sympathomimetic activity by isopropyl-2'-phenoxymethyl-2-imidazoline
KR910018026A (en) Drugs for treating urination disorders containing α-phenyl-αpyridylalkanoic acid derivatives
IT1265224B1 (en) Pharmaceutical compositions for oral use for the treatment of ulcerous gastro-duodenal and oesophageal conditions
KR920700041A (en) Therapeutic Compounds and Their Composition and Uses
RU98109932A (en) APPLICATION OF 1- (2-NAFT-2-YLETHYL) -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETHRHYDROPYRIDINE FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF LATERAL AMYOTRAFRAZIC

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8304818-1

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8304818-1

Format of ref document f/p: F